✦ LIBER ✦

No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy

✍ Scribed by E. Petru; D. Schmähl

Book ID: 112296328
Publisher: Springer-Verlag
Year: 1988
Tongue: English
Weight: 217 KB
Volume: 114
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf00417834

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of cytotoxic chemotherapy on s

Influence of cytotoxic chemotherapy on survival in patients with metastatic breast cancer

✍ L. Jaspers; K. Possinger; W. Wilmanns; P. Langecker; M. Morgalla 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 138 KB

PCN3 CORRELATION BETWEEN TIME TO PROGRES

PCN3 CORRELATION BETWEEN TIME TO PROGRESSION AND OVERALL SURVIVAL IN PATIENTS WITH METASTATIC BREAST CANCER

✍ B Sherrill; C Hirst; Y Wu; MM Amonkar; S Stein 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Impact of the first tumor response at ei

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

✍ Chikako Suzuki, Lennart Blomqvist, Thomas Hatschek, Lena Carlsson, Zakaria Einbe 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 306 KB

Improved survival of patients with metas

Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s

✍ Michael B. Ross; Aman U. Buzdar; Terry L. Smith; Nylene Eckles; Gabriel N. Horto 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 546 KB

Phase II Trial of Nab-Paclitaxel Compare

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

✍ William J. Gradishar; Dimitry Krasnojon; Sergey Cheporov; Anatoly N. Makhson; Ge 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 380 KB

Overall Survival Benefit With Lapatinib

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

✍ Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H. S.; Sledge, G.; Ak 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 203 KB